secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001193125-22-217954
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics promotes Mel Hayes to COO with salary increase and stock option grant
--------------------------------------------------------------------------------

- Mel Hayes promoted from chief commercial officer to chief operating officer effective August 9, 2022.
- Annual base salary increased to $453,000 retroactive to July 1, 2022.
- Granted option to purchase 137,000 shares at $7.40 per share, vesting over four years.
- Hayes previously served as CCO since September 2021; prior roles include Sanofi-Genzyme and Bioverativ.
- Employment agreement setting terms for severance and change-in-control benefits filed as Exhibit 10.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522217954/0001193125-22-217954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522217954/d346123d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-217954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer